SARS-CoV-2 Variant P1 (Isolate: Japan/TY7-503/2021) – CFHI
SARS-Related Coronavirus 2 Variant Brazil P.1 (Isolate: Japan/TY7-503/2021) is an enveloped, positive-sense single-stranded RNA virus from the Coronaviridae family and the Betacoronaviridae genus. Severe acute respiratory syndrome-related coronavirus 2 (SARS CoV-2), isolate hCoV-19/Japan/TY7-503/2021 (Brazil P.1) (also referred to as TY7-503, hCoV-19/Japan/IC-0564/2021) was isolated in airport quarantine in Japan from a COVID-19 positive passenger from Brazil in January 2021. Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate hCoV- 19/Japan/TY7-503/2021 (Brazil P.1) is assigned lineage P.1 and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINeages (PANGOLIN) tool. The complete genome of SARSCoV-2, isolate hCoV-19/Japan/TY7-503/2021 (Brazil P.1) has been sequenced Clinical isolate (referred to as hCoV-19/Japan/IC-0564/2021): GISAID: EPI_ISL_792683. Each frozen aliquot contains 1 mL of heat inactivated viral culture fluid. The culture fluid was clarified prior to heat inactivation by centrifugation to remove cellular debris. The pre-inactivation titer was determined from an infectious aliquot. Viral inactivation is verified after heat inactivation by the absence of viral growth in tissue culture-based infectivity assays.
Heat inactivated viral culture fluids are sold as consumable testing materials. The suitability andperformance characteristics should be determined by your laboratory for each intended usage. These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under section 351 of the Public Health Service Act or for any other product intended for administration to humans.
For BSL-2 or BSL-3 compliant labs only. CCL required / -20° C.